演題番号 : P1-p02
濱田 健吾 / Kengo Hamada:1 辰巳 晃子 / Kouko Tatsumi:1 奥田 洋明 / Hiroaki Okuda:1 山内 崇平 / Takahira Yamauchi:2 紀本 創兵 / Souhei Kimoto:2 岸本 年史 / Toshifumi Kishimoto:2 和中 明生 / Akio Wanaka:1
1:奈良県立医科大学・医・第2解剖学 / Anatomy and Neuroscience, Nara Medical University 2:奈良県立医科大学・精神医学教室 / Department of Psychiatry, Nara Medical University, Kashihara, Nara, Japan
Accumulating evidence indicates that schizophrenic patients have white matter abnormalities in the brain, suggesting the involvement of oligodendrocytes in the etiopathology of schizophrenia. For example, gene microarray studies showed the downregulation of genes related to oligodendrocyte function and myelination in the brain of patients. There is, however, little information about pharmacological agents that can target oligodendrocytes in the schizophrenic brain. In this study, we examined the effects of Yokukansan (TJ-54), one of the traditional "Kampo" medicines, on the tissue and behaviors of a schizophrenia animal model. Cuprizone (CPZ)-treated mouse was employed, because this is one of the best characterized demyelinating model and is recently recognized as schizophrenia model as well. CPZ is a copper chelator and has been known to specifically damage to the myelin sheath and oligodendrocytes, but not to cause lesions in other cell types in the central nervous system.